Dr. Solin on Personalizing Treatment With the DCIS Score

Lawrence J. Solin, MD
Published: Tuesday, Feb 28, 2012

Lawrence J. Solin, MD, chair, Department of Radiation Oncology, Einstein Medical Center, discusses a few of the differences between the Oncotype DX recurrence score and the new 12-gene assay for patients with ductal carcinoma in situ (DCIS), labeled the DCIS Score.

The DCIS Score, derived from the multigene RT-PCR assay, should be used for noninvasive DCIS tumors while the Oncotype DX test is primarily used for invasive tumors and carcinomas. Differences exist between the way the results of these tests are calculated and their impact on the treatment process.

Predicting the individual risk for local recurrence in patients with DCIS allows physicians to make personalized treatment decisions. Whether or not to provide radiation or tamoxifen can be aided by how the patient’s risk is categorized.

Lawrence J. Solin, MD, chair, Department of Radiation Oncology, Einstein Medical Center, discusses a few of the differences between the Oncotype DX recurrence score and the new 12-gene assay for patients with ductal carcinoma in situ (DCIS), labeled the DCIS Score.

The DCIS Score, derived from the multigene RT-PCR assay, should be used for noninvasive DCIS tumors while the Oncotype DX test is primarily used for invasive tumors and carcinomas. Differences exist between the way the results of these tests are calculated and their impact on the treatment process.

Predicting the individual risk for local recurrence in patients with DCIS allows physicians to make personalized treatment decisions. Whether or not to provide radiation or tamoxifen can be aided by how the patient’s risk is categorized.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x